CYLD is a negative regulator of TRAF2 and NF-kappa B signaling pathway. CYLD has a deubiquitinating activity that is directed towards non-Lys48-linked polyubiquitin chains. Defects in CYLD are the cause of familial cylindromatosis, a highly tumor type-specific disorder.
List price: $0.00
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease
Signaling Molecules and Interaction
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
Probable ubiquitin carboxyl-terminal hydrolase CYLD; Ubiquitin thioesterase CYLD; Ubiquitin-specific-processing protease CYLD; Deubiquitinating enzyme CYLD; CYLD1
The synthetic peptide used to raise the antibody Cat. No. 200136 is selected from a sequence within the N-term region of human CYLD. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Purity > 80% by HPLC
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Monday, December 17, 2012